JTE-451 / Japan Tobacco, Orphagen - LARVOL DELTA

IMPACT-PS: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2; N=152; Completed; Sponsor: Akros Pharma Inc.; Active, not recruiting ➔ Completed; Trial completion date: Jul 2020 ➔ Feb 2020

Clinical • Trial completion • Trial completion date

IMPACT-PS: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2; N=150; Active, not recruiting; Sponsor: Akros Pharma Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

IMPACT-PS: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2; N=150; Recruiting; Sponsor: Akros Pharma Inc.

Clinical • New P2 trial